Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,263 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,163
Recruiting: 2,261
Ph III recruiting: 268
Growth YoY: +12.8%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,897)

clinicaltrialsPublishedShowing 751–800 of 2,265 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03587311	Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 2	96	National Cancer Institute (NCI)NIH	2	Jul 8, 2026	clinicaltrials
NCT03747120	Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]	active not recruiting	Phase 2	138	University of Texas Southwestern Medical CenterOTHER	1	Jul 8, 2026